Recovery | Persistent Myopathy | Death | p Value | |
Stage D on day 1 [n = 38] | ||||
Gender | 0.443* | |||
Female | 39% | 26% | 35% | |
Male | 20% | 27% | 53% | |
LVSF, % (mean ± SD) | 15.3 ± 3.6 | 16.7 ± 3.1 | 12.3 ± 3.4 | 0.01† |
LVEDD 95% (mean ± SD) | 105.9 ± 15.4 | 107.8 ± 20.4 | 107.2 ± 28.3 | 0.916† |
Stage D on day 5 [n = 19] | ||||
Gender | 0.01* | |||
Female | 66% | 17% | 17% | |
Male | 0% | 43% | 57% | |
LVSF, % (mean ± SD) | 14 ± 3.5 | 15.2 ± 2.4 | 11.5 ± 2.7 | 0.096† |
LVEDD 95% (mean ± SD) | 106.6 ± 18.8 | 107.7 ± 23.8 | 118.6 ± 30.7 | 0.748† |